Democratic Congress could mean FDA rule over biotech generics

11/21/2006 | Wall Street Journal, The · Reuters

The change in control of Congress could mean Democrats will introduce legislation to give FDA the authority to approve follow-on biologics. Biotech companies say their products are too complicated to recreate, generics would need clinical trials to ensure the safety and efficacy of their copycat products, and a push for generics could impede R&D efforts.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA